Showing 5571-5580 of 7686 results for "".
- Can Phages Help Treat AD?https://practicaldermatology.com/news/can-phages-help-treat-adp/2462033/Bacteriophages or bacteria eaters may be a new therapy option for people with atopic dermatitis (AD), according to a study in Science Advances. A MedUni Vienna team has investigated t
- Nevisense Detects Skin Barrier Damage In Skin Sampleshttps://practicaldermatology.com/news/nevisense-detects-skin-barrier-damage-in-skin-samples/2462031/Nevisense can measure skin barrier function in human excised skin samples, SciBase reports. For the study, Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of commercially available detergents on the skin barrier of mice
- Scrubbing Behind the Ears and Between the Toes May Help Keep These Skin Areas Healthyhttps://practicaldermatology.com/news/scrubbing-behind-the-ears-and-between-the-toes-may-help-keep-this-skin-healthy/2462030/Skin behind the ears and between the toes can host a collection of unhealthy microbes, according to a new study by a team at the George Washington University. Researchers at the GW Computational Biology Institute wanted to take a closer look at the skin microbiome of healthy
- NEA Launches #OneThingAboutEczema Campaign for Eczema Awareness Monthhttps://practicaldermatology.com/news/nea-launches-onethingabouteczema-campaign-for-eczema-awareness-month/2462029/The National Eczema Association (NEA) is highlighting different aspects of living with eczema for its annua
- Abeona Submits BLA for RDEB Treatmenthttps://practicaldermatology.com/news/abeona-submits-bla-for-rdeb-treatment/2462026/Abeona Therapeutics Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). <
- Cosmo, Glenmark Sign Distribution and License Agreements for Winlevi in Europe and South Africahttps://practicaldermatology.com/news/cosmo-glenmark-sign-distribution-and-license-agreements-for-winlevi-in-europe-and-south-africa/2462024/Glenmark Pharmaceuticals Ltd., now has exclusive rights to commercialize Winlevi (clascoterone cream 1%) in 15 EU countries (Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal,
- Arcutis Launches Educational Campaign for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-educational-campaign-for-people-living-with-seborrheic-dermatitis/2462021/Arcutis Biotherapeutics, Inc. is launching
- UCB Anticipates Delay for FDA Bimekizumab Decisionhttps://practicaldermatology.com/news/ucb-anticipates-delay-for-fda-bimekizumab-decision/2462017/The anticipated Biologics License Application (BLA) for bimekizumab to treat plaque psoriasis will likely be delayed beyond Q3 2023, according to a statement from UCB. Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) an
- Exploring the Link Between Sex Hormones and Melanoma Riskhttps://practicaldermatology.com/news/exploring-the-link-between-sex-hormones-and-melanoma-risk/2462016/Researchers out of the University of Tennessee Health Science Center are beginning a study to determine whether sex hormones affect the risk of melanoma The team received a $423,500 grant from the National Institute of Environmental Health Sciences, part of the National Institutes of He
- Does Vitiligo-associated Autoimmunity Reduce Morbidity and Mortality?https://practicaldermatology.com/news/does-vitiligo-associated-autoimmunity-reduced-morbidity-and-mortality/2462014/Vitiligo-associated autoimmunity may play a role in reducing morbidity and mortality, according to a study in the Journal of Investigative Dermatology. When researchers investigated the mortality of patients with vitiligo in a population-base